Cohance Lifesciences: USFDA inspection at Pashamylaram facility classified VAI

Cohance Lifesciences Ltd has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pashamylaram manufacturing facility. The inspection outcome has been classified as Voluntary Action Indicated (VAI). With the issuance of the EIR, the USFDA inspection process for this facility is now concluded. This classification suggests that while the USFDA noted some areas for improvement, they do not currently require a specific regulatory response beyond what the company may voluntarily undertake.